OptiNose Inc. Stock News

Cubist Systematic Strategies LLC lowered its position in OptiNose, Inc. (NASDAQ:OPTN) by 43.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,951 shares of the companys stock after selling 13,081 shares during the quarter. Cubist Systematic Strategies LLCs holdings in OptiNose were worth $53,000 []

OptiNose (NASDAQ:OPTN)s stock had its overweight rating reissued by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Zacks.com reports. Several other research analysts also recently commented on OPTN. Zacks Investment Research raised shares of OptiNose from a hold rating to a buy rating and set a $1.75 price target on the stock []

Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a hold rating to a buy rating in a research note published on Friday morning, Zacks.com reports. They currently have $1.75 target price on the stock. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for []

OptiNose (NASDAQ:OPTN) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.75 price target on the stock. Zacks Investment Researchs price target indicates a potential upside of 3.55% from the companys current price. According to []

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Piper Sandler 33 rd Annual Virtual Healthcare Conference scheduled for November 29 through December, 2, 2021.

OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.

OptiNose, Inc. (NASDAQ:OPTN) Piper Sandler issued their Q1 2023 earnings per share (EPS) estimates for OptiNose in a research note issued to investors on Friday, November 19th. Piper Sandler analyst D. Amsellem anticipates that the company will post earnings per share of ($0.10) for the quarter. Piper Sandler also issued estimates for OptiNoses Q2 []

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that

OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.

In the last trading session, 1.1 million shares of the OptiNose Inc. (NASDAQ:OPTN) were traded, and its beta was 0.83. Most recently the companys share price was $1.58, and it changed around -$0.04 or -2.47% from the last close, which brings the market valuation of the company to $86.60M. OPTN currently trades at a discount Why OptiNose Inc. (NASDAQ: OPTN) Stock Should Not Be Taken For Granted By Investors In 2021 Read More »

The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i

The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i

Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a hold rating to a buy rating in a research report sent to investors on Saturday morning, Zacks.com reports. The brokerage currently has $1.75 price objective on the stock. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization []

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announ